Evidence map›Paper›PMID 22906957›Full record

ReviewThe American journal of medicine2012

Hypertension and chronic kidney disease progression: why the suboptimal outcomes?

Anil K Bidani, Karen A Griffin, Murray Epstein

Abstract readReview
In one paragraph

Review in The American journal of medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Observational
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin.Clinical research in cardiology : official journal of the German Cardiac Society · 2015
    Review
  11. Article
  12. Article
  13. Review
  14. Renal microvascular dysfunction, hypertension and CKD progression.Current opinion in nephrology and hypertension · 2013
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Anil K BidaniDepartment of Medicine, Loyola University Chicago, USA.
Karen A Griffin
Murray Epstein
Loyola University Chicago · USUniversity of Miami · US

Funding

Dynamic BP load and diabetic nephropathy phenotype.R01DK061653 · NIDDK · LOYOLA UNIVERSITY CHICAGO · PI GRIFFIN, KAREN A. · 2002 to 2014
$2.1M
NIDDK NIH HHS R01 DK061653
6 · The paper itself

Abstract

Current therapeutic interventions to retard the progression of chronic kidney disease have yielded disappointing outcomes despite adequate renin-angiotensin system blockade. The parameters to gauge the adequacy of blood pressure control need to be reassessed because clinic blood pressure constitutes a poor gauge of such control. The biologically relevant parameter for hypertensive target organ damage is total blood pressure burden, and reliance on isolated clinic blood pressure measurements per se does not accurately reflect the total blood pressure burden. This is particularly relevant to the population with chronic kidney disease in whom masked daytime or nocturnal hypertension and blood pressure lability are both widely prevalent and more difficult to control. Consequently, it is possible that the limited success currently being achieved in preventing or attenuating chronic kidney disease progression may be attributable in part to suboptimal 24-hour blood pressure control. Recent data and analyses also indicate that blood pressure variability, instability, episodic and nocturnal blood pressure elevations, and maximum systolic blood pressure may constitute additional strong predictors of the risk of target organ damage independently of mean systolic blood pressure. Accordingly, we suggest that future research should include the development of safe and effective strategies to achieve around-the-clock blood pressure control in addition to targeting mechanisms that reduce intrarenal blood pressure transmission or interrupt subsequent downstream pathways. Meanwhile, more aggressive use of patient education and home blood pressure monitoring with selection of longer-acting antihypertensive agents or nocturnal dosing should be considered to improve the current suboptimal results.

Indexed as

Antihypertensive AgentsBlood PressureBlood Pressure DeterminationDisease ProgressionHumansHypertensionRenal Insufficiency, ChronicAntihypertensive Agents

Identifiers

PMID22906957
PMCPMC3943135
OpenAlexW1985164614

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.